A freshly minted S-1 filing for Anthropic’s IPO hit the wire last week. The initial read: a carbon copy of SpaceX’s non-voting share structure, designed to keep control with the founding team. But there’s a difference buried in the fine print that changes the risk calculus entirely. Anthropic is a Delaware public benefit corporation. That one clause creates a legal ambiguity that most retail investors—and even some institutional allocators—are treating as a footnote. In my experience, footnotes are where the bodies are buried.
Anthropic, the AI safety company behind Claude, has been positioning itself as the ethical alternative to OpenAI. The narrative is seductive: build safe AI, attract top talent, and eventually IPO with a governance model that protects the mission from short-term shareholder pressure. The SpaceX playbook gave them a template: issue non-voting shares to the public while a special class of stock with supermajority voting rights stays with the founders. That part is well-understood. The difference is that SpaceX is a traditional Delaware corporation. Anthropic is a benefit corporation, which means its directors are legally permitted—and in some states required—to consider non-financial stakeholders, not just shareholders.
Let’s deconstruct the governance structure from first principles. A benefit corporation charter typically includes a “public benefit purpose” and a duty to balance shareholder value with that purpose. In Delaware, the benefit corporation statute explicitly shields directors from liability for decisions that prioritize the public benefit over profit. This is a powerful tool for a founder who wants to ignore an activist investor demanding a dividend. But it also creates a legal black hole. If the company underperforms, shareholders cannot easily sue for breach of fiduciary duty because the duty is bifurcated. The board can always say, “We chose the public benefit.” The question is: who defines that benefit? The board itself. That’s an unfalsifiable shield.
During my audit of the 0x protocol in 2018, I learned that the most dangerous vulnerabilities are not in the code but in the assumptions. The 0x team assumed integer overflow would be caught by standard tests—it wasn’t. Here, the assumption is that a benefit corporation structure will protect the mission. In reality, it protects the board from accountability. The voting structure is already non-dilutive for the founders. Adding a benefit corporation mandate gives them a legal excuse to ignore shareholder value entirely. This is not a safety feature; it’s a governance poison pill.
The data from the S-1 is revealing. The company plans to issue Class A shares with no voting rights. Class B shares, held by founders and early investors, have 10 votes per share. The board is staggered, and shareholder proposals require a supermajority of Class B votes. Standard stuff. But the benefit corporation clause adds a twist: the board is required to “balance” the interests of shareholders, employees, and the public. In practice, this means any decision—from a takeover defense to a capital allocation choice—can be justified by appealing to the public benefit. There is no legal mechanism for shareholders to challenge that justification unless it is demonstrably irrational. Good luck proving that in court.
Hype is leverage in reverse. The market is pricing Anthropic’s IPO as a premium AI play. The narrative of “safe AI” is driving demand. But the governance structure means that the leverage is entirely one-sided. The founders hold all the upside control; the public holds all the downside risk. If the company fails to meet financial targets, the board can blame the public benefit mandate. If the company succeeds, the founders capture the value. This asymmetry is a red flag that should be flashing in every due diligence report.
I’ve seen this pattern before. In 2020, during the Compound Treasury drain analysis, I modeled how flash loan vulnerabilities were systematically underestimated because the community focused on the interest rate model’s elegance rather than the edge cases. The governance of Anthropic is similarly elegant—a benefit corporation designed to protect the mission. But the edge case is the one where the mission becomes a pretext for poor management. The directors are not accountable to shareholders in any meaningful way. The charter does not specify how to measure the public benefit. There is no independent auditor for the benefit corporation obligations. It’s a trust-me structure.
Code is law, but capital is king. In blockchain, we often say that code is law. But the governance of a traditional corporation is not code; it’s a legal contract. And that contract has a gap. The benefit corporation statute was designed for companies like Patagonia or Ben & Jerry’s, where the mission is clear and the market is small. Anthropic is a high-stakes AI company with a potential valuation of $60 billion. The gap between the legal structure and the operational reality is enormous. The founders are betting that the benefit corporation shield will protect them from shareholder pressure. But what happens when the AI safety mission conflicts with the need to raise capital at a reasonable rate? The board can simply choose the mission and issue more shares at a discount, diluting public investors. The poison pill is already in place.
The contrarian view is that the benefit corporation structure actually aligns incentives for long-term value creation. The argument is that by protecting the company from short-termism, the founders can invest in safety research that would otherwise be cut. I’ve heard this argument before, from the founders of a certain DeFi project that promised to “build for the long term” while ignoring slippage risks. The difference is that the DeFi project had a governance token that could be used to vote out the founders. Anthropic’s public shareholders have no voting rights and no legal recourse. The only exit is selling the shares on the secondary market—at a price determined by the market’s perception of the board’s decisions. And the board has no obligation to maximize that price.
Takeaway: The Anthropic IPO is a test case for how far governance can be stretched before it breaks. The benefit corporation clause is not a feature; it’s a liability. Investors should demand a clear framework for how the public benefit will be measured and enforced. Without that, the IPO is a bet on the integrity of the founders, not on the strength of the governance. In a bull market, that bet might pay off. But when the cycle turns, the lack of accountability will be exposed. And the only people left holding the bag will be the public shareholders who bought the mission without reading the fine print.